The company announced it has progressed its Phase 1 clinical trial of NTX1088 by incorporating a combination therapy arm featuring the immune-oncology drug KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and broadened the clinical trial to five global sites including: Ochsner Health MD Anderson Cancer Center in Louisiana, City of Hope in California, Sheba Medical Center, Tel Hashomer and Hadassah Medical Center in Israel, along with MD Anderson Cancer Center in Houston, Texas.
NTX1088 is Nectin’s first-in-class lead candidate – a highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors. PVR blockade by NTX1088 is the first and only therapeutic approach aimed at restoring the antitumor immune activity of DNAM1 (CD226). Restoring the expression and activation of DNAM1 by blocking PVR results in increased antitumor activity from T-cells and NK cells.
